Objective:

2

To evaluate the immediate effect of Kuanxiong Aerosol (KXA) on perioperative coronary microcirculation in patients with unstable angina (UA) suffering from elective percutaneous coronary intervention (PCI).

Methods:

2

From February 2021 to July 2023

UA inpatients who underwent PCI alone in the left anterior descending (LAD) branch were included. Random numbers were generated to divide patients into the trial group and the control group at a ratio of 1:1. The index of coronary microcirculation resistance (IMR) was measured before PCI

and the trial group was given two sprays of KXA

while the control group was not given. IMR was measured again after PCI

cardiac troponin I (cTnI) and creatine kinase isoenzyme-MB (CK-MB) were detected before and 24 h after surgery

and major cardiovascular adverse events (MACEs) were recorded for 30 days. The data statistics and analysis personnel were blinded.

Results:

2

Totally 859 patients were screened

and 62 of them were involved into this study. Finally

1 patient in the trial group failed to complete the post-PCI IMR and was excluded

30 patients were included for data analysis

while 31 patients in the control group were enrolled in data analysis. There was no significant difference in baseline data (age

gender

risk factors

previous history

biochemical index

and drug therapy

etc.) between the two groups. In addition

differences in IMR

cTnI and CK-MB were not statistically significant between the two groups before surgery. After PCI

the IMR level of the trial group was significantly lower than that of the control group (19.56±14.37

vs

. 27.15±15.03

P

=0.048). Besides

the incidence of perioperative myocardial injury (PMI) was lower in the trial group

but the difference was not statistically significant (6.67%

vs

.16.13%

P

=0.425). No MACEs were reported in either group.

Conclusions:

2

KXA has the potential of improving coronary microvascular dysfunction. This study provides reference for the application of KXA in UA patients undergoing elective PCI. (Registration No. ChiCTR2300069831)